MSD's oral HIF-2 alpha inhibitor Welireg has a third FDA approval, becoming the first oral treatment for a rare form of solid ...

France's Sanofi is the latest European pharma group to promise a big capital investment programme on manufacturing and R&D in ...

However, trust gaps among clinicians and patients are threatening to slow the adoption and impact of AI. Among HCPs, ...

AbbVie has claimed its first regulatory approval, from the FDA, for its C-met-targeting antibody-drug conjugate (ADC) Emrelis ...

US Health and Human Services (HHS) Secretary Robert F Kennedy Jr has made his first testimonies in front of Congress since he ...

Join the 4th Process Development for Cell Therapies Summit to hear from 24+ industry leaders from biopharma and service ...

Since December 2022, and COP decision 15/9, members of the Convention on Biological Diversity (the CBD) have been negotiating ...

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston ...

What if we could reprogramme the TME itself? Cutting-edge research suggests that engineered mesenchymal stem cells (MSCs) ...

That’s it for 2025’s Q1 clinical trials round-up. If you have a study that could fit the bill for our next column, please ...

Andrew Witty has resigned as chief executive of US health conglomerate UnitedHealth Group, as the company pulled its ...

The drive revolves around a "10-for-one" policy laid out in a Trump executive order at the end of January, which demanded ...